Lantheus received approval from the U.S. Food and Drug Administration (FDA) in May 2021 for Pylarify (F-18 DCFPyL), a PET radiotracer that targets PSMA, with clearance for Pylarify AI following in July.

Pylarify AI uses a deep-learning algorithm that has been trained and validated on more than 3,000 images. It allows healthcare professionals and researchers to perform standardized quantitative assessment of PSMA-PET/CT images.

PSMA is a protein expressed on prostate cancer cells. Imaging and quantifying PSMA in patients with suspected prostate cancer can help clinicians determine…